| 1 | Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the <scp>OCEAN study</scp> | 1.9 | 2 | Citations (PDF) |
| 2 | Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from <scp>GRIFFIN</scp> | 6.1 | 3 | Citations (PDF) |
| 3 | Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk | 7.9 | 21 | Citations (PDF) |
| 4 | Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the <scp>BOSTON</scp> trial | 1.9 | 10 | Citations (PDF) |
| 5 | Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN | 7.9 | 27 | Citations (PDF) |
| 6 | An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of <scp>SAR442085</scp> in patients with relapsed or refractory multiple myeloma | 1.9 | 1 | Citations (PDF) |
| 7 | Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence | 2.4 | 11 | Citations (PDF) |
| 8 | Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide | 2.0 | 9 | Citations (PDF) |
| 9 | Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm | 7.9 | 12 | Citations (PDF) |
| 10 | Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials | 2.0 | 49 | Citations (PDF) |
| 11 | Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy | 7.9 | 16 | Citations (PDF) |
| 12 | Selinexor: Targeting a novel pathway in multiple myeloma | 1.7 | 21 | Citations (PDF) |
| 13 | Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT) | 3.3 | 76 | Citations (PDF) |
| 14 | Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial | 1.7 | 1 | Citations (PDF) |
| 15 | A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma | 2.7 | 5 | Citations (PDF) |
| 16 | Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes | 2.4 | 52 | Citations (PDF) |
| 17 | Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics | 1.9 | 9 | Citations (PDF) |
| 18 | Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study | 2.4 | 10 | Citations (PDF) |
| 19 | Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant | 5.1 | 30 | Citations (PDF) |
| 20 | Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma | 10.4 | 26 | Citations (PDF) |
| 21 | The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma | 1.9 | 6 | Citations (PDF) |
| 22 | DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma | 1.0 | 0 | Citations (PDF) |
| 23 | Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma | 1.0 | 38 | Citations (PDF) |
| 24 | Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study | 9.2 | 60 | Citations (PDF) |
| 25 | Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma | 6.1 | 4 | Citations (PDF) |
| 26 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study | 26.0 | 109 | Citations (PDF) |
| 27 | An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment | 3.0 | 7 | Citations (PDF) |
| 28 | Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma | 4.1 | 33 | Citations (PDF) |
| 29 | Extramedullary disease in multiple myeloma: a systematic literature review | 7.9 | 223 | Citations (PDF) |
| 30 | Defibrotide Therapy for SARS-CoV-2 ARDSChest, 2022, 162, 346-355 | 1.1 | 11 | Citations (PDF) |
| 31 | Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma | 43.7 | 390 | Citations (PDF) |
| 32 | Melflufen for the treatment of multiple myeloma | 2.7 | 5 | Citations (PDF) |
| 33 | Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma | 1.5 | 5 | Citations (PDF) |
| 34 | Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee | 7.9 | 50 | Citations (PDF) |
| 35 | Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review | 2.4 | 18 | Citations (PDF) |
| 36 | Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the <scp>GRIFFIN</scp> study | 2.4 | 21 | Citations (PDF) |
| 37 | Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis | 4.1 | 30 | Citations (PDF) |
| 38 | Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation | 2.0 | 5 | Citations (PDF) |
| 39 | Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study | 26.0 | 61 | Citations (PDF) |
| 40 | Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma | 1.7 | 11 | Citations (PDF) |
| 41 | Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial | 9.2 | 115 | Citations (PDF) |
| 42 | Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins | 6.4 | 101 | Citations (PDF) |
| 43 | Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | 7.9 | 12 | Citations (PDF) |
| 44 | A clinical perspective on plasma cell leukemia; current status and future directions | 7.9 | 56 | Citations (PDF) |
| 45 | Molecular dynamics of targeting CD38 in multiple myeloma | 2.4 | 25 | Citations (PDF) |
| 46 | Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations | 2.4 | 144 | Citations (PDF) |
| 47 | Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaBlood, 2021, 137, 3616-3628 | 4.2 | 88 | Citations (PDF) |
| 48 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group | 26.0 | 222 | Citations (PDF) |
| 49 | Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma | 30.9 | 15 | Citations (PDF) |
| 50 | Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation | 4.9 | 120 | Citations (PDF) |
| 51 | Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis | 0.7 | 29 | Citations (PDF) |
| 52 | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma | 10.4 | 16 | Citations (PDF) |
| 53 | Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma | 6.1 | 21 | Citations (PDF) |
| 54 | Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics | 2.4 | 46 | Citations (PDF) |
| 55 | ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment | 11.0 | 23 | Citations (PDF) |
| 56 | Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design | 2.4 | 30 | Citations (PDF) |
| 57 | Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications? | 2.1 | 42 | Citations (PDF) |
| 58 | Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma | 1.0 | 18 | Citations (PDF) |
| 59 | Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes | 3.9 | 14 | Citations (PDF) |
| 60 | Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma | 10.4 | 67 | Citations (PDF) |
| 61 | Selinexor for the treatment of patients with previously treated multiple myeloma | 2.0 | 7 | Citations (PDF) |
| 62 | Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk | 6.1 | 31 | Citations (PDF) |
| 63 | Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | 21.6 | 89 | Citations (PDF) |
| 64 | Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in<i>BRAF</i>-Mutated Multiple Myeloma | 6.9 | 26 | Citations (PDF) |
| 65 | Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study | 2.4 | 15 | Citations (PDF) |
| 66 | A phase I/<scp>II</scp> study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance <scp>A061202</scp>) | 6.1 | 20 | Citations (PDF) |
| 67 | Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study | 3.1 | 12 | Citations (PDF) |
| 68 | Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options | 5.2 | 46 | Citations (PDF) |
| 69 | The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae | 3.3 | 17 | Citations (PDF) |
| 70 | Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma | 16.9 | 41 | Citations (PDF) |
| 71 | Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma | 1.0 | 99 | Citations (PDF) |
| 72 | A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma | 6.9 | 92 | Citations (PDF) |
| 73 | Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation | 1.6 | 21 | Citations (PDF) |
| 74 | Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement | 9.2 | 73 | Citations (PDF) |
| 75 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study | 26.0 | 715 | Citations (PDF) |
| 76 | Proteasome inhibition for the treatment of glioblastoma | 4.0 | 38 | Citations (PDF) |
| 77 | Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myelomaBlood, 2020, 136, 2513-2523 | 4.2 | 71 | Citations (PDF) |
| 78 | Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study | 7.9 | 48 | Citations (PDF) |
| 79 | Isatuximab for the treatment of relapsed/refractory multiple myeloma | 3.1 | 36 | Citations (PDF) |
| 80 | Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | 1.0 | 5 | Citations (PDF) |
| 81 | Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial | 26.0 | 223 | Citations (PDF) |
| 82 | Melflufen for relapsed and refractory multiple myeloma | 4.0 | 21 | Citations (PDF) |
| 83 | Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial | 52.8 | 289 | Citations (PDF) |
| 84 | Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialBlood, 2020, 136, 936-945 | 4.2 | 618 | Citations (PDF) |
| 85 | Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant | 13.9 | 149 | Citations (PDF) |
| 86 | The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift? | 2.4 | 30 | Citations (PDF) |
| 87 | c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma | 1.9 | 9 | Citations (PDF) |
| 88 | Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd | 2.0 | 44 | Citations (PDF) |
| 89 | Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma | 2.7 | 88 | Citations (PDF) |
| 90 | Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients | 1.6 | 28 | Citations (PDF) |
| 91 | Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study | 9.2 | 71 | Citations (PDF) |
| 92 | Selinexor for the treatment of multiple myeloma | 2.2 | 59 | Citations (PDF) |
| 93 | Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation | 1.9 | 19 | Citations (PDF) |
| 94 | Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib | 1.7 | 11 | Citations (PDF) |
| 95 | Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma | 1.5 | 12 | Citations (PDF) |
| 96 | Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | 10.4 | 54 | Citations (PDF) |
| 97 | Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials | 9.2 | 96 | Citations (PDF) |
| 98 | Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis | 10.4 | 61 | Citations (PDF) |
| 99 | Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma | 2.6 | 47 | Citations (PDF) |
| 100 | Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma | 0.4 | 1 | Citations (PDF) |
| 101 | Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM | 4.0 | 4 | Citations (PDF) |
| 102 | HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis | 4.2 | 1 | Citations (PDF) |
| 103 | Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation | 1.6 | 46 | Citations (PDF) |
| 104 | Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma | 43.7 | 597 | Citations (PDF) |
| 105 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study | 52.8 | 569 | Citations (PDF) |
| 106 | Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma | 6.1 | 55 | Citations (PDF) |
| 107 | Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome | 1.0 | 5 | Citations (PDF) |
| 108 | Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance | 10.4 | 47 | Citations (PDF) |
| 109 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial | 26.0 | 339 | Citations (PDF) |
| 110 | A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myelomaBlood, 2019, 134, 123-133 | 4.2 | 91 | Citations (PDF) |
| 111 | Deciphering the chronology of copy number alterations in Multiple Myeloma | 7.9 | 46 | Citations (PDF) |
| 112 | Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy | 10.4 | 28 | Citations (PDF) |
| 113 | Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies | 1.9 | 12 | Citations (PDF) |
| 114 | Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) | 3.3 | 66 | Citations (PDF) |
| 115 | Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older | 1.8 | 37 | Citations (PDF) |
| 116 | Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era | 2.4 | 9 | Citations (PDF) |
| 117 | A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma | 6.9 | 41 | Citations (PDF) |
| 118 | Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results | 2.4 | 34 | Citations (PDF) |
| 119 | Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design | 2.4 | 69 | Citations (PDF) |
| 120 | Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome | 2.7 | 30 | Citations (PDF) |
| 121 | Current use of monoclonal antibodies in the treatment of multiple myeloma | 2.4 | 44 | Citations (PDF) |
| 122 | Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing | 10.4 | 54 | Citations (PDF) |
| 123 | Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1 | 10.4 | 14 | Citations (PDF) |
| 124 | A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results | 2.4 | 71 | Citations (PDF) |
| 125 | CD38 antibodies in multiple myeloma: back to the future | 4.2 | 417 | Citations (PDF) |
| 126 | The use of defibrotide in blood and marrow transplantation | 5.1 | 66 | Citations (PDF) |
| 127 | Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting | 7.9 | 216 | Citations (PDF) |
| 128 | The power of proteasome inhibition in multiple myeloma | 2.1 | 34 | Citations (PDF) |
| 129 | Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial | 26.0 | 226 | Citations (PDF) |
| 130 | Ixazomib for the treatment of multiple myeloma | 2.2 | 60 | Citations (PDF) |
| 131 | Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | 43.7 | 495 | Citations (PDF) |
| 132 | Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myelomaBlood, 2018, 132, 2456-2464 | 4.2 | 378 | Citations (PDF) |
| 133 | Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial | 4.1 | 127 | Citations (PDF) |
| 134 | Patient‐reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double‐blind, placebo‐controlled <scp>PANORAMA</scp>‐1 trial | 2.4 | 22 | Citations (PDF) |
| 135 | Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study | 2.4 | 36 | Citations (PDF) |
| 136 | Final results from a defibrotide treatment‐<scp>IND</scp> study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome | 2.4 | 119 | Citations (PDF) |
| 137 | How I treat the young patient with multiple myelomaBlood, 2018, 132, 1114-1124 | 4.2 | 41 | Citations (PDF) |
| 138 | Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma | 2.4 | 32 | Citations (PDF) |
| 139 | Maintenance and continuous therapy for multiple myeloma | 2.6 | 13 | Citations (PDF) |
| 140 | Trial designs for chemotherapy-induced peripheral neuropathy prevention | 1.0 | 82 | Citations (PDF) |
| 141 | A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma | 2.4 | 147 | Citations (PDF) |
| 142 | Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma | 6.1 | 43 | Citations (PDF) |
| 143 | Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma | 2.4 | 39 | Citations (PDF) |
| 144 | Defibrotide for the treatment of hepatic veno‐occlusive disease/sinusoidal obstruction syndrome following nontransplant‐associated chemotherapy: Final results from a post hoc analysis of data from an expanded‐access program | 1.4 | 32 | Citations (PDF) |
| 145 | APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications | 10.4 | 73 | Citations (PDF) |
| 146 | Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma | 6.9 | 243 | Citations (PDF) |
| 147 | Deacetylase inhibitors: an advance in myeloma therapy? | 2.0 | 26 | Citations (PDF) |
| 148 | p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myelomaBlood, 2017, 129, 1308-1319 | 4.2 | 44 | Citations (PDF) |
| 149 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma | 2.4 | 53 | Citations (PDF) |
| 150 | A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma | 2.4 | 49 | Citations (PDF) |
| 151 | Earlier defibrotide initiation post‐diagnosis of veno‐occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation | 2.4 | 87 | Citations (PDF) |
| 152 | Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis | 1.9 | 24 | Citations (PDF) |
| 153 | Impact of concomitant dexamethasone dosing schedule on bortezomib‐induced peripheral neuropathy in multiple myeloma | 2.4 | 23 | Citations (PDF) |
| 154 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma | 43.7 | 1,143 | Citations (PDF) |
| 155 | IgM myeloma: A multicenter retrospective study of 134 patients | 6.1 | 52 | Citations (PDF) |
| 156 | Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group | 26.0 | 486 | Citations (PDF) |
| 157 | Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study | 1.6 | 54 | Citations (PDF) |
| 158 | Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsBlood, 2017, 130, 2610-2618 | 4.2 | 109 | Citations (PDF) |
| 159 | Realgar nanoparticles <i>versus </i><scp>ATO</scp> arsenic compounds induce <i>in vitro</i> and <i>in vivo</i> activity <i>against</i> multiple myeloma | 2.4 | 38 | Citations (PDF) |
| 160 | Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses | 3.3 | 20 | Citations (PDF) |
| 161 | Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation | 2.5 | 28 | Citations (PDF) |
| 162 | Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial | 9.2 | 155 | Citations (PDF) |
| 163 | Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women | 10.4 | 32 | Citations (PDF) |
| 164 | IgA multiple myeloma in a patient with an IgG pemphigus foliaceus‐like exanthem | 2.2 | 2 | Citations (PDF) |
| 165 | Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent | 2.0 | 12 | Citations (PDF) |
| 166 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth | 2.4 | 128 | Citations (PDF) |
| 167 | Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
<i>vs</i>
. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 | 4.1 | 52 | Citations (PDF) |
| 168 | The proteasome and proteasome inhibitors in multiple myeloma | 7.2 | 304 | Citations (PDF) |
| 169 | Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against | 2.2 | 10 | Citations (PDF) |
| 170 | Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma | 1.0 | 44 | Citations (PDF) |
| 171 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaBlood, 2017, 130, 1198-1204 | 4.2 | 61 | Citations (PDF) |
| 172 | Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial | 2.4 | 20 | Citations (PDF) |
| 173 | Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma | 9.4 | 28 | Citations (PDF) |
| 174 | Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies | 14.6 | 95 | Citations (PDF) |
| 175 | Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multiorgan Failure | 2.6 | 31 | Citations (PDF) |
| 176 | New developments in the management of relapsed/refractory multiple myeloma &ndash; the role of ixazomib | 2.4 | 19 | Citations (PDF) |
| 177 | Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study | 30.9 | 62 | Citations (PDF) |
| 178 | Melflufen - a peptidase-potentiated alkylating agent in clinical trials | 1.7 | 79 | Citations (PDF) |
| 179 | Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma | 3.6 | 26 | Citations (PDF) |
| 180 | A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications | 1.7 | 57 | Citations (PDF) |
| 181 | Safety of Live-attenuated Zoster Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide after Autologous Stem Cell Transplantation. | 0.8 | 0 | Citations (PDF) |
| 182 | Safety of MMR Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation. | 0.8 | 0 | Citations (PDF) |
| 183 | <scp>TAK</scp>‐228 (formerly <scp>MLN</scp>0128), an investigational oral dual <scp>TORC</scp>1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia | 6.1 | 94 | Citations (PDF) |
| 184 | Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma | 2.4 | 12 | Citations (PDF) |
| 185 | Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaBlood, 2016, 128, 1821-1828 | 4.2 | 106 | Citations (PDF) |
| 186 | Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research | 1.6 | 55 | Citations (PDF) |
| 187 | Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | 43.7 | 985 | Citations (PDF) |
| 188 | Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cellsBlood, 2016, 127, 1138-1150 | 4.2 | 109 | Citations (PDF) |
| 189 | Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myelomaBlood, 2016, 127, 681-695 | 4.2 | 193 | Citations (PDF) |
| 190 | Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failureBlood, 2016, 127, 1656-1665 | 4.2 | 303 | Citations (PDF) |
| 191 | Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Blood, 2016, 127, 2693-2700 | 4.2 | 75 | Citations (PDF) |
| 192 | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma | 4.2 | 379 | Citations (PDF) |
| 193 | Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentBlood, 2016, 127, 713-721 | 4.2 | 129 | Citations (PDF) |
| 194 | Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma | 6.9 | 21 | Citations (PDF) |
| 195 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | 43.7 | 1,360 | Citations (PDF) |
| 196 | Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program | 1.6 | 87 | Citations (PDF) |
| 197 | Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients | 2.4 | 50 | Citations (PDF) |
| 198 | Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma | 3.1 | 15 | Citations (PDF) |
| 199 | Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial | 26.0 | 187 | Citations (PDF) |
| 200 | APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironmentBlood, 2016, 127, 3225-3236 | 4.2 | 304 | Citations (PDF) |
| 201 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | 26.0 | 2,576 | Citations (PDF) |
| 202 | Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial | 9.2 | 142 | Citations (PDF) |
| 203 | Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma | 7.6 | 135 | Citations (PDF) |
| 204 | A novel alkylating agent Melflufen induces irreversible <scp>DNA</scp> damage and cytotoxicity in multiple myeloma cells | 2.4 | 56 | Citations (PDF) |
| 205 | Multiple Myeloma in Pregnancy—A Review of the Literature and a Case Series | 1.0 | 14 | Citations (PDF) |
| 206 | Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution | 6.9 | 29 | Citations (PDF) |
| 207 | Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial | 52.8 | 801 | Citations (PDF) |
| 208 | The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival | 13.9 | 102 | Citations (PDF) |
| 209 | Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes | 2.7 | 27 | Citations (PDF) |
| 210 | Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws | 1.6 | 4 | Citations (PDF) |
| 211 | First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose EscalationBlood, 2016, 128, 1148-1148 | 4.2 | 24 | Citations (PDF) |
| 212 | Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaBlood, 2016, 128, 2122-2122 | 4.2 | 1 | Citations (PDF) |
| 213 | Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple MyelomaBlood, 2016, 128, 2123-2123 | 4.2 | 19 | Citations (PDF) |
| 214 | Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)Blood, 2016, 128, 243-243 | 4.2 | 3 | Citations (PDF) |
| 215 | Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label StudyBlood, 2016, 128, 3326-3326 | 4.2 | 6 | Citations (PDF) |
| 216 | Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study | 4.2 | 3 | Citations (PDF) |
| 217 | Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)Blood, 2016, 128, 675-675 | 4.2 | 38 | Citations (PDF) |
| 218 | Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple MyelomaBlood, 2016, 128, 976-976 | 4.2 | 20 | Citations (PDF) |
| 219 | IgM Myeloma: A Multicenter Retrospective Study of 159 PatientsBlood, 2016, 128, 3276-3276 | 4.2 | 0 | Citations (PDF) |
| 220 | Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)Blood, 2016, 128, 2134-2134 | 4.2 | 0 | Citations (PDF) |
| 221 | Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other CancersBlood, 2016, 128, 5689-5689 | 4.2 | 1 | Citations (PDF) |
| 222 | Resolving the daratumumab interference with blood compatibility testing | 0.8 | 222 | Citations (PDF) |
| 223 | Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | 4.1 | 32 | Citations (PDF) |
| 224 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015, 125, 2068-2074 | 4.2 | 699 | Citations (PDF) |
| 225 | Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD<sup>®</sup>immunomodulatory drug pomalidomide | 2.4 | 46 | Citations (PDF) |
| 226 | Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells | 2.4 | 22 | Citations (PDF) |
| 227 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | 43.7 | 1,254 | Citations (PDF) |
| 228 | Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study | 9.2 | 145 | Citations (PDF) |
| 229 | Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit | 1.0 | 1 | Citations (PDF) |
| 230 | Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study | 6.1 | 63 | Citations (PDF) |
| 231 | Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival | 1.6 | 3 | Citations (PDF) |
| 232 | Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant | 1.6 | 24 | Citations (PDF) |
| 233 | Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma | 6.9 | 298 | Citations (PDF) |
| 234 | Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma | 25.6 | 105 | Citations (PDF) |
| 235 | CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon | 6.9 | 41 | Citations (PDF) |
| 236 | Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens | 2.4 | 19 | Citations (PDF) |
| 237 | The Investigational Proteasome Inhibitor Ixazomib for the Treatment of Multiple Myeloma | 2.4 | 26 | Citations (PDF) |
| 238 | Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations | 2.4 | 77 | Citations (PDF) |
| 239 | Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma | 43.7 | 1,058 | Citations (PDF) |
| 240 | Panobinostat for the Treatment of Multiple Myeloma | 6.9 | 257 | Citations (PDF) |
| 241 | Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)Blood, 2015, 126, 1827-1827 | 4.2 | 10 | Citations (PDF) |
| 242 | Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma | 4.2 | 37 | Citations (PDF) |
| 243 | Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up | 4.2 | 22 | Citations (PDF) |
| 244 | A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated MechanismBlood, 2015, 126, 3000-3000 | 4.2 | 1 | Citations (PDF) |
| 245 | Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free SurvivalBlood, 2015, 126, 3029-3029 | 4.2 | 1 | Citations (PDF) |
| 246 | Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal ImpairmentBlood, 2015, 126, 3031-3031 | 4.2 | 3 | Citations (PDF) |
| 247 | A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)Blood, 2015, 126, 3036-3036 | 4.2 | 12 | Citations (PDF) |
| 248 | ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)Blood, 2015, 126, 3040-3040 | 4.2 | 20 | Citations (PDF) |
| 249 | Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)Blood, 2015, 126, 3055-3055 | 4.2 | 7 | Citations (PDF) |
| 250 | Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I ResultsBlood, 2015, 126, 375-375 | 4.2 | 19 | Citations (PDF) |
| 251 | Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)Blood, 2015, 126, 391-391 | 4.2 | 102 | Citations (PDF) |
| 252 | Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 TrialBlood, 2015, 126, 395-395 | 4.2 | 22 | Citations (PDF) |
| 253 | A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple MyelomaBlood, 2015, 126, 4217-4217 | 4.2 | 8 | Citations (PDF) |
| 254 | Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple MyelomaBlood, 2015, 126, 4220-4220 | 4.2 | 7 | Citations (PDF) |
| 255 | Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)Blood, 2015, 126, 4228-4228 | 4.2 | 20 | Citations (PDF) |
| 256 | Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)Blood, 2015, 126, 4246-4246 | 4.2 | 2 | Citations (PDF) |
| 257 | Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple MyelomaBlood, 2015, 126, 4256-4256 | 4.2 | 4 | Citations (PDF) |
| 258 | Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)Blood, 2015, 126, 507-507 | 4.2 | 30 | Citations (PDF) |
| 259 | Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 TrialBlood, 2015, 126, 737-737 | 4.2 | 1 | Citations (PDF) |
| 260 | Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By PomalidomideBlood, 2015, 126, 4253-4253 | 4.2 | 0 | Citations (PDF) |
| 261 | Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative StudyBlood, 2015, 126, 5322-5322 | 4.2 | 0 | Citations (PDF) |
| 262 | Targeting Replicative Stress to Treat Hematological DisordersBlood, 2015, 126, 2419-2419 | 4.2 | 0 | Citations (PDF) |
| 263 | A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceBlood, 2014, 123, 706-716 | 4.2 | 284 | Citations (PDF) |
| 264 | Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition | 0.6 | 72 | Citations (PDF) |
| 265 | Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area | 21.6 | 23 | Citations (PDF) |
| 266 | Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsBlood, 2014, 124, 1038-1046 | 4.2 | 200 | Citations (PDF) |
| 267 | Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? | 2.9 | 25 | Citations (PDF) |
| 268 | Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study | 26.0 | 249 | Citations (PDF) |
| 269 | Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide | 2.4 | 39 | Citations (PDF) |
| 270 | Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy | 6.9 | 36 | Citations (PDF) |
| 271 | A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaBlood, 2014, 123, 1461-1469 | 4.2 | 181 | Citations (PDF) |
| 272 | Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy | 38.5 | 918 | Citations (PDF) |
| 273 | Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data | 26.0 | 271 | Citations (PDF) |
| 274 | Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers | 39.5 | 281 | Citations (PDF) |
| 275 | Heterogeneity of genomic evolution and mutational profiles in multiple myeloma | 13.9 | 818 | Citations (PDF) |
| 276 | International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation | 21.6 | 373 | Citations (PDF) |
| 277 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | 26.0 | 4,298 | Citations (PDF) |
| 278 | Novel Targeted Agents in the Treatment of Multiple Myeloma | 2.3 | 17 | Citations (PDF) |
| 279 | Allogeneic Transplantation in Multiple Myeloma: A Potential Renaissance in the Era of Novel Therapies? | 1.6 | 1 | Citations (PDF) |
| 280 | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | 26.0 | 753 | Citations (PDF) |
| 281 | The challenge of cross-trial comparisons using limited data | 4.1 | 7 | Citations (PDF) |
| 282 | Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapyBlood, 2014, 123, 632-639 | 4.2 | 111 | Citations (PDF) |
| 283 | Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myelomaBlood, 2014, 123, 3128-3138 | 4.2 | 450 | Citations (PDF) |
| 284 | Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood, 2014, 123, 1826-1832 | 4.2 | 355 | Citations (PDF) |
| 285 | Differential and limited expression of mutant alleles in multiple myelomaBlood, 2014, 124, 3110-3117 | 4.2 | 55 | Citations (PDF) |
| 286 | Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy | 4.1 | 48 | Citations (PDF) |
| 287 | Current treatment landscape for relapsed and/or refractory multiple myeloma | 75.5 | 191 | Citations (PDF) |
| 288 | Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 PatientsBlood, 2014, 124, 1138-1138 | 4.2 | 1 | Citations (PDF) |
| 289 | Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing MethodBlood, 2014, 124, 2036-2036 | 4.2 | 1 | Citations (PDF) |
| 290 | Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple MyelomaBlood, 2014, 124, 2120-2120 | 4.2 | 4 | Citations (PDF) |
| 291 | Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom MacroglobulinemiaBlood, 2014, 124, 3081-3081 | 4.2 | 16 | Citations (PDF) |
| 292 | Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results | 4.2 | 11 | Citations (PDF) |
| 293 | Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label StudyBlood, 2014, 124, 3453-3453 | 4.2 | 17 | Citations (PDF) |
| 294 | Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple MyelomaBlood, 2014, 124, 3483-3483 | 4.2 | 14 | Citations (PDF) |
| 295 | Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)Blood, 2014, 124, 4764-4764 | 4.2 | 13 | Citations (PDF) |
| 296 | Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple MyelomaBlood, 2014, 124, 4772-4772 | 4.2 | 8 | Citations (PDF) |
| 297 | Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma PatientsBlood, 2014, 124, 638-638 | 4.2 | 26 | Citations (PDF) |
| 298 | Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results | 4.2 | 19 | Citations (PDF) |
| 299 | SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents OsteoclastogenesisBlood, 2014, 124, 3441-3441 | 4.2 | 26 | Citations (PDF) |
| 300 | Mimicking Myeloma Niche Ex VivoBlood, 2014, 124, 2076-2076 | 4.2 | 0 | Citations (PDF) |
| 301 | Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof TechnologyBlood, 2014, 124, 3404-3404 | 4.2 | 0 | Citations (PDF) |
| 302 | Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma | 4.2 | 2 | Citations (PDF) |
| 303 | Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive DiseaseBlood, 2014, 124, 2470-2470 | 4.2 | 0 | Citations (PDF) |
| 304 | Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom MacroglobulinemiaBlood, 2014, 124, 2070-2070 | 4.2 | 0 | Citations (PDF) |
| 305 | Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy | 1.0 | 41 | Citations (PDF) |
| 306 | Conservative management of bisphosphonate-related osteonecrosis of the jaws: Staging and treatment outcomes | 2.5 | 51 | Citations (PDF) |
| 307 | The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias | 2.2 | 65 | Citations (PDF) |
| 308 | Evolving Strategies in the Initial Treatment of Multiple Myeloma | 1.9 | 5 | Citations (PDF) |
| 309 | Clinical Translation in Multiple Myeloma: From Bench to Bedside | 1.9 | 9 | Citations (PDF) |
| 310 | Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma | 0.7 | 48 | Citations (PDF) |
| 311 | Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humansBlood, 2013, 121, 2975-2987 | 4.2 | 376 | Citations (PDF) |
| 312 | Pomalidomide: New immunomodulatory agent with potent antiproliferative effects | 5.2 | 36 | Citations (PDF) |
| 313 | Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study | 2.4 | 20 | Citations (PDF) |
| 314 | New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors | 2.4 | 39 | Citations (PDF) |
| 315 | <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells | 6.9 | 98 | Citations (PDF) |
| 316 | Kidney Disease and Multiple Myeloma | 4.4 | 145 | Citations (PDF) |
| 317 | Drug safety evaluation of defibrotide | 2.7 | 76 | Citations (PDF) |
| 318 | Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibBlood, 2013, 121, 1961-1967 | 4.2 | 161 | Citations (PDF) |
| 319 | PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaBlood, 2013, 122, 2331-2337 | 4.2 | 289 | Citations (PDF) |
| 320 | Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activityBlood, 2013, 122, 1243-1255 | 4.2 | 79 | Citations (PDF) |
| 321 | The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction | 0.0 | 0 | Citations (PDF) |
| 322 | Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple MyelomaBlood, 2013, 122, 1869-1869 | 4.2 | 2 | Citations (PDF) |
| 323 | MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)Blood, 2013, 122, 1969-1969 | 4.2 | 12 | Citations (PDF) |
| 324 | Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple MyelomaBlood, 2013, 122, 1970-1970 | 4.2 | 4 | Citations (PDF) |
| 325 | A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple MyelomaBlood, 2013, 122, 1976-1976 | 4.2 | 15 | Citations (PDF) |
| 326 | Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's MacroglobulinemiaBlood, 2013, 122, 4402-4402 | 4.2 | 5 | Citations (PDF) |
| 327 | Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 DataBlood, 2013, 122, 535-535 | 4.2 | 20 | Citations (PDF) |
| 328 | ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)Blood, 2013, 122, 759-759 | 4.2 | 19 | Citations (PDF) |
| 329 | New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors | 2.4 | 1 | Citations (PDF) |
| 330 | Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple MyelomaBlood, 2013, 122, 4429-4429 | 4.2 | 0 | Citations (PDF) |
| 331 | High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)Blood, 2013, 122, 1854-1854 | 4.2 | 0 | Citations (PDF) |
| 332 | Proton Pump Inhibitors | 11.8 | 121 | Citations (PDF) |
| 333 | Proteasome Inhibition | 0.1 | 0 | Citations (PDF) |
| 334 | Management Strategies for Relapsed Multiple Myeloma | 0.1 | 1 | Citations (PDF) |
| 335 | Emerging Therapies for Multiple Myeloma | 0.1 | 1 | Citations (PDF) |
| 336 | Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma | 6.9 | 80 | Citations (PDF) |
| 337 | Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaBlood, 2012, 119, 4375-4382 | 4.2 | 431 | Citations (PDF) |
| 338 | Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma | 1.8 | 52 | Citations (PDF) |
| 339 | Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease | 3.0 | 42 | Citations (PDF) |
| 340 | Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune functionBlood, 2012, 119, e131-e138 | 4.2 | 29 | Citations (PDF) |
| 341 | IMWG consensus on maintenance therapy in multiple myelomaBlood, 2012, 119, 3003-3015 | 4.2 | 181 | Citations (PDF) |
| 342 | A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomideBlood, 2012, 119, 2764-2767 | 4.2 | 147 | Citations (PDF) |
| 343 | Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cellsBlood, 2012, 120, 3958-3967 | 4.2 | 73 | Citations (PDF) |
| 344 | How I treat plasma cell leukemiaBlood, 2012, 120, 2376-2389 | 4.2 | 130 | Citations (PDF) |
| 345 | Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneBlood, 2012, 120, 4513-4516 | 4.2 | 77 | Citations (PDF) |
| 346 | Methyljasmonate displays <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma cells | 2.4 | 28 | Citations (PDF) |
| 347 | Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myelomaBlood, 2012, 119, 5772-5781 | 4.2 | 392 | Citations (PDF) |
| 348 | A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance | 38.5 | 565 | Citations (PDF) |
| 349 | Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity | 2.8 | 104 | Citations (PDF) |
| 350 | Management of myeloma-associated renal dysfunction in the era of novel therapies | 2.0 | 31 | Citations (PDF) |
| 351 | Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation | 2.0 | 47 | Citations (PDF) |
| 352 | Latest advances and current challenges in the treatment of multiple myeloma | 75.5 | 197 | Citations (PDF) |
| 353 | New Proteasome Inhibitors in Myeloma | 2.8 | 90 | Citations (PDF) |
| 354 | Proteasome inhibitors in multiple myeloma: 10 years laterBlood, 2012, 120, 947-959 | 4.2 | 475 | Citations (PDF) |
| 355 | Lenalidomide for the treatment of relapsed and refractory multiple myeloma | 2.0 | 29 | Citations (PDF) |
| 356 | Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone | 21.6 | 10 | Citations (PDF) |
| 357 | Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma | 43.7 | 1,091 | Citations (PDF) |
| 358 | Pathological crystallization of human immunoglobulins | 7.6 | 38 | Citations (PDF) |
| 359 | The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* | 1.9 | 7 | Citations (PDF) |
| 360 | The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib | 1.9 | 11 | Citations (PDF) |
| 361 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study | 2.4 | 56 | Citations (PDF) |
| 362 | PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple MyelomaBlood, 2012, 120, 1852-1852 | 4.2 | 7 | Citations (PDF) |
| 363 | A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated ResultsBlood, 2012, 120, 202-202 | 4.2 | 18 | Citations (PDF) |
| 364 | Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)Blood, 2012, 120, 4039-4039 | 4.2 | 3 | Citations (PDF) |
| 365 | Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 StudyBlood, 2012, 120, 4052-4052 | 4.2 | 2 | Citations (PDF) |
| 366 | Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)Blood, 2012, 120, 4053-4053 | 4.2 | 4 | Citations (PDF) |
| 367 | Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment ExposureBlood, 2012, 120, 4070-4070 | 4.2 | 1 | Citations (PDF) |
| 368 | Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient OutcomesBlood, 2012, 120, 4072-4072 | 4.2 | 5 | Citations (PDF) |
| 369 | Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup AnalysisBlood, 2012, 120, 450-450 | 4.2 | 11 | Citations (PDF) |
| 370 | Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study | 4.2 | 62 | Citations (PDF) |
| 371 | Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple MyelomaBlood, 2012, 120, 3986-3986 | 4.2 | 12 | Citations (PDF) |
| 372 | Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow MicroenvironmentBlood, 2012, 120, 565-565 | 4.2 | 2 | Citations (PDF) |
| 373 | Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) CellsBlood, 2012, 120, 1847-1847 | 4.2 | 0 | Citations (PDF) |
| 374 | Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple MyelomaBlood, 2012, 120, 1812-1812 | 4.2 | 0 | Citations (PDF) |
| 375 | Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic AgentsBlood, 2012, 120, 3995-3995 | 4.2 | 0 | Citations (PDF) |
| 376 | <i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells | 6.9 | 300 | Citations (PDF) |
| 377 | Multiple Myeloma | 19.5 | 139 | Citations (PDF) |
| 378 | Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma | 21.6 | 80 | Citations (PDF) |
| 379 | Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma | 2.0 | 23 | Citations (PDF) |
| 380 | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc | 34.1 | 2,665 | Citations (PDF) |
| 381 | Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study | 26.0 | 94 | Citations (PDF) |
| 382 | Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaBlood, 2011, 117, 393-402 | 4.2 | 213 | Citations (PDF) |
| 383 | Genetic variation associated with bortezomib-induced peripheral neuropathy | 1.3 | 64 | Citations (PDF) |
| 384 | Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsBlood, 2011, 117, 4409-4419 | 4.2 | 150 | Citations (PDF) |
| 385 | Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011, 117, 4691-4695 | 4.2 | 953 | Citations (PDF) |
| 386 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011, 117, 6063-6073 | 4.2 | 295 | Citations (PDF) |
| 387 | Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialBlood, 2011, 118, 535-543 | 4.2 | 84 | Citations (PDF) |
| 388 | Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy | 4.1 | 62 | Citations (PDF) |
| 389 | Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers | 2.4 | 123 | Citations (PDF) |
| 390 | Molecular and cellular effects of multi‐targeted cyclin‐dependent kinase inhibition in myeloma: biological and clinical implications | 2.4 | 24 | Citations (PDF) |
| 391 | Characterization of haematological parameters with bortezomib–melphalan–prednisone <i>versus</i> melphalan–prednisone in newly diagnosed myeloma, with evaluation of long‐term outcomes and risk of thromboembolic events with use of erythropoiesis‐stimulating agents: analysis of the VISTA trial | 2.4 | 14 | Citations (PDF) |
| 392 | Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study | 2.4 | 103 | Citations (PDF) |
| 393 | Monoclonal antibodies in the treatment of multiple myeloma | 2.4 | 70 | Citations (PDF) |
| 394 | Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings | 2.4 | 20 | Citations (PDF) |
| 395 | Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study | 1.9 | 136 | Citations (PDF) |
| 396 | A novel panel of protein biomarkers for predicting response to thalidomide‐based therapy in newly diagnosed multiple myeloma patients | 3.1 | 34 | Citations (PDF) |
| 397 | A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma | 6.1 | 21 | Citations (PDF) |
| 398 | Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma | 1.8 | 260 | Citations (PDF) |
| 399 | Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma | 4.1 | 75 | Citations (PDF) |
| 400 | Treatment Options for Relapsed and Refractory Multiple Myeloma | 6.9 | 119 | Citations (PDF) |
| 401 | A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma | 1.5 | 28 | Citations (PDF) |
| 402 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study | 10.4 | 708 | Citations (PDF) |
| 403 | Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple MyelomaBlood, 2011, 118, 133-133 | 4.2 | 2 | Citations (PDF) |
| 404 | A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety DataBlood, 2011, 118, 1873-1873 | 4.2 | 2 | Citations (PDF) |
| 405 | Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple MyelomaBlood, 2011, 118, 1874-1874 | 4.2 | 1 | Citations (PDF) |
| 406 | Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein ResponseBlood, 2011, 118, 1881-1881 | 4.2 | 11 | Citations (PDF) |
| 407 | Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's MacroglobulinemiaBlood, 2011, 118, 2705-2705 | 4.2 | 1 | Citations (PDF) |
| 408 | Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom MacroglobulinemiaBlood, 2011, 118, 2706-2706 | 4.2 | 1 | Citations (PDF) |
| 409 | Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)Blood, 2011, 118, 2933-2933 | 4.2 | 5 | Citations (PDF) |
| 410 | Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation StudyBlood, 2011, 118, 301-301 | 4.2 | 10 | Citations (PDF) |
| 411 | Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)Blood, 2011, 118, 302-302 | 4.2 | 30 | Citations (PDF) |
| 412 | A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaBlood, 2011, 118, 303-303 | 4.2 | 8 | Citations (PDF) |
| 413 | Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,Blood, 2011, 118, 3966-3966 | 4.2 | 2 | Citations (PDF) |
| 414 | Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,Blood, 2011, 118, 3968-3968 | 4.2 | 1 | Citations (PDF) |
| 415 | Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA TrialBlood, 2011, 118, 476-476 | 4.2 | 18 | Citations (PDF) |
| 416 | Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)Blood, 2011, 118, 479-479 | 4.2 | 5 | Citations (PDF) |
| 417 | Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access ProtocolBlood, 2011, 118, 487-487 | 4.2 | 3 | Citations (PDF) |
| 418 | Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 ResultsBlood, 2011, 118, 634-634 | 4.2 | 11 | Citations (PDF) |
| 419 | Inhibition of c-Myc Expression and Function in Hematologic MalignanciesBlood, 2011, 118, 1409-1409 | 4.2 | 0 | Citations (PDF) |
| 420 | Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II TrialBlood, 2011, 118, 815-815 | 4.2 | 0 | Citations (PDF) |
| 421 | RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,Blood, 2011, 118, 4134-4134 | 4.2 | 0 | Citations (PDF) |
| 422 | Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic IndexBlood, 2011, 118, 1442-1442 | 4.2 | 0 | Citations (PDF) |
| 423 | Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer GenesBlood, 2011, 118, 1377-1377 | 4.2 | 0 | Citations (PDF) |
| 424 | A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma CellsBlood, 2011, 118, 1841-1841 | 4.2 | 0 | Citations (PDF) |
| 425 | Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,Blood, 2011, 118, 3989-3989 | 4.2 | 0 | Citations (PDF) |
| 426 | Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated KillingBlood, 2011, 118, 1838-1838 | 4.2 | 5 | Citations (PDF) |
| 427 | PI3K/p110δ is a novel therapeutic target in multiple myelomaBlood, 2010, 116, 1460-1468 | 4.2 | 185 | Citations (PDF) |
| 428 | A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaBlood, 2010, 115, 5202-5213 | 4.2 | 267 | Citations (PDF) |
| 429 | Kidney disease associated with plasma cell dyscrasiasBlood, 2010, 116, 1397-1404 | 4.2 | 53 | Citations (PDF) |
| 430 | Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisoneBlood, 2010, 116, 3743-3750 | 4.2 | 102 | Citations (PDF) |
| 431 | A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myelomaBlood, 2010, 116, 4906-4915 | 4.2 | 196 | Citations (PDF) |
| 432 | Improving the therapeutic index in myelomaBlood, 2010, 116, 4733-4734 | 4.2 | 4 | Citations (PDF) |
| 433 | Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myelomaBlood, 2010, 115, 834-845 | 4.2 | 107 | Citations (PDF) |
| 434 | Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia | 12.9 | 39 | Citations (PDF) |
| 435 | Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaBlood, 2010, 116, 3227-3237 | 4.2 | 215 | Citations (PDF) |
| 436 | The evolution and impact of therapy in multiple myeloma | 2.4 | 34 | Citations (PDF) |
| 437 | Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity <i>in vitro</i> and <i>in vivo</i> | 2.4 | 124 | Citations (PDF) |
| 438 | Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma | 2.4 | 72 | Citations (PDF) |
| 439 | Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study | 2.4 | 74 | Citations (PDF) |
| 440 | THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT | 0.8 | 2 | Citations (PDF) |
| 441 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010, 116, 679-686 | 4.2 | 838 | Citations (PDF) |
| 442 | Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma | 6.9 | 72 | Citations (PDF) |
| 443 | Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial | 4.1 | 39 | Citations (PDF) |
| 444 | Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–2 | 3.1 | 5 | Citations (PDF) |
| 445 | Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group | 21.6 | 384 | Citations (PDF) |
| 446 | Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome | 1.6 | 573 | Citations (PDF) |
| 447 | Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial | 1.6 | 232 | Citations (PDF) |
| 448 | Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury | 1.6 | 93 | Citations (PDF) |
| 449 | Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma | 26.0 | 7 | Citations (PDF) |
| 450 | Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple MyelomaBlood, 2010, 116, 1943-1943 | 4.2 | 2 | Citations (PDF) |
| 451 | A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated PopulationBlood, 2010, 116, 1951-1951 | 4.2 | 17 | Citations (PDF) |
| 452 | A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent MechanismBlood, 2010, 116, 3007-3007 | 4.2 | 1 | Citations (PDF) |
| 453 | Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma DrugsBlood, 2010, 116, 3013-3013 | 4.2 | 13 | Citations (PDF) |
| 454 | Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic AnalysisBlood, 2010, 116, 3051-3051 | 4.2 | 4 | Citations (PDF) |
| 455 | Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).Blood, 2010, 116, 3481-3481 | 4.2 | 5 | Citations (PDF) |
| 456 | Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts).Blood, 2010, 116, 3482-3482 | 4.2 | 3 | Citations (PDF) |
| 457 | Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom MacroglobulinemiaBlood, 2010, 116, 3952-3952 | 4.2 | 9 | Citations (PDF) |
| 458 | Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION StudyBlood, 2010, 116, 621-621 | 4.2 | 15 | Citations (PDF) |
| 459 | Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access ProtocolBlood, 2010, 116, 906-906 | 4.2 | 3 | Citations (PDF) |
| 460 | Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 StudyBlood, 2010, 116, 986-986 | 4.2 | 6 | Citations (PDF) |
| 461 | Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to BortezomibBlood, 2010, 116, 990-990 | 4.2 | 5 | Citations (PDF) |
| 462 | Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and DexamethasoneBlood, 2010, 116, 618-618 | 4.2 | 0 | Citations (PDF) |
| 463 | MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome InhibitorsBlood, 2010, 116, 2988-2988 | 4.2 | 2 | Citations (PDF) |
| 464 | An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling PathwayBlood, 2010, 116, 2992-2992 | 4.2 | 0 | Citations (PDF) |
| 465 | Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In MyelomaBlood, 2010, 116, 456-456 | 4.2 | 7 | Citations (PDF) |
| 466 | Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each CycleBlood, 2010, 116, 1963-1963 | 4.2 | 1 | Citations (PDF) |
| 467 | Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions.Blood, 2010, 116, 1574-1574 | 4.2 | 28 | Citations (PDF) |
| 468 | Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune FunctionBlood, 2010, 116, 451-451 | 4.2 | 0 | Citations (PDF) |
| 469 | Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell DegranulationBlood, 2010, 116, 4064-4064 | 4.2 | 0 | Citations (PDF) |
| 470 | Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 StudyBlood, 2010, 116, 3023-3023 | 4.2 | 9 | Citations (PDF) |
| 471 | Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic ImplicationsBlood, 2010, 116, 5016-5016 | 4.2 | 0 | Citations (PDF) |
| 472 | Bortezomib in the management of multiple myeloma | 2.0 | 9 | Citations (PDF) |
| 473 | Novel Therapies in the Treatment of Multiple Myeloma | 12.9 | 38 | Citations (PDF) |
| 474 | Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia | 1.5 | 33 | Citations (PDF) |
| 475 | Use of defibrotide in the treatment and prevention of veno-occlusive disease | 2.0 | 15 | Citations (PDF) |
| 476 | Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib | 6.9 | 67 | Citations (PDF) |
| 477 | Emerging therapies for multiple myeloma | 2.4 | 52 | Citations (PDF) |
| 478 | Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cellsBlood, 2009, 114, 1046-1052 | 4.2 | 352 | Citations (PDF) |
| 479 | Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target | 38.5 | 266 | Citations (PDF) |
| 480 | Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline | 2.4 | 297 | Citations (PDF) |
| 481 | Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma | 2.4 | 80 | Citations (PDF) |
| 482 | Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma | 2.4 | 28 | Citations (PDF) |
| 483 | <i>In vitro</i> anti‐myeloma activity of the Aurora kinase inhibitor VE‐465 | 2.4 | 27 | Citations (PDF) |
| 484 | Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib | 3.2 | 54 | Citations (PDF) |
| 485 | Multiple myeloma | 52.8 | 728 | Citations (PDF) |
| 486 | The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity | 1.0 | 40 | Citations (PDF) |
| 487 | Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implicationsBlood, 2009, 113, 5228-5236 | 4.2 | 70 | Citations (PDF) |
| 488 | Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myelomaBlood, 2009, 114, 772-778 | 4.2 | 149 | Citations (PDF) |
| 489 | How I treat multiple myeloma in younger patientsBlood, 2009, 114, 5436-5443 | 4.2 | 124 | Citations (PDF) |
| 490 | Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.Blood, 2009, 114, 127-127 | 4.2 | 19 | Citations (PDF) |
| 491 | Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.Blood, 2009, 114, 132-132 | 4.2 | 7 | Citations (PDF) |
| 492 | Lack of Response to Vaccination in MGUS and Stable Myeloma.Blood, 2009, 114, 1852-1852 | 4.2 | 11 | Citations (PDF) |
| 493 | Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.Blood, 2009, 114, 1871-1871 | 4.2 | 4 | Citations (PDF) |
| 494 | Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.Blood, 2009, 114, 2878-2878 | 4.2 | 18 | Citations (PDF) |
| 495 | Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.Blood, 2009, 114, 2890-2890 | 4.2 | 7 | Citations (PDF) |
| 496 | Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.Blood, 2009, 114, 654-654 | 4.2 | 13 | Citations (PDF) |
| 497 | Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy | 2.0 | 19 | Citations (PDF) |
| 498 | Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.Blood, 2009, 114, 950-950 | 4.2 | 0 | Citations (PDF) |
| 499 | Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.Blood, 2009, 114, 2846-2846 | 4.2 | 3 | Citations (PDF) |
| 500 | A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.Blood, 2009, 114, 3830-3830 | 4.2 | 1 | Citations (PDF) |
| 501 | PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo.Blood, 2009, 114, 612-612 | 4.2 | 0 | Citations (PDF) |
| 502 | The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma | 2.4 | 95 | Citations (PDF) |
| 503 | Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma | 2.4 | 95 | Citations (PDF) |
| 504 | Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma | 2.4 | 90 | Citations (PDF) |
| 505 | Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study | 2.4 | 58 | Citations (PDF) |
| 506 | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma | 43.7 | 1,839 | Citations (PDF) |
| 507 | Bortezomib in the front-line treatment of multiple myeloma | 2.6 | 81 | Citations (PDF) |
| 508 | Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma | 1.5 | 187 | Citations (PDF) |
| 509 | Re: When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival | 4.7 | 7 | Citations (PDF) |
| 510 | Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma | 21.6 | 158 | Citations (PDF) |
| 511 | Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study | 21.6 | 257 | Citations (PDF) |
| 512 | Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaBlood, 2008, 111, 1654-1664 | 4.2 | 195 | Citations (PDF) |
| 513 | Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuBlood, 2008, 112, 1329-1337 | 4.2 | 463 | Citations (PDF) |
| 514 | Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive diseaseBlood, 2008, 112, 4343-4352 | 4.2 | 60 | Citations (PDF) |
| 515 | Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantationBlood, 2008, 112, 4425-4431 | 4.2 | 156 | Citations (PDF) |
| 516 | Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias | 2.0 | 3 | Citations (PDF) |
| 517 | The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo | 0.1 | 2 | Citations (PDF) |
| 518 | A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | 2.1 | 35 | Citations (PDF) |
| 519 | Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.Blood, 2008, 112, 1011-1011 | 4.2 | 1 | Citations (PDF) |
| 520 | A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.Blood, 2008, 112, 1719-1719 | 4.2 | 2 | Citations (PDF) |
| 521 | Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple MyelomaBlood, 2008, 112, 3662-3662 | 4.2 | 3 | Citations (PDF) |
| 522 | Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)Blood, 2008, 112, 3691-3691 | 4.2 | 12 | Citations (PDF) |
| 523 | Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple MyelomaBlood, 2008, 112, 3696-3696 | 4.2 | 26 | Citations (PDF) |
| 524 | Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaBlood, 2008, 112, 3700-3700 | 4.2 | 7 | Citations (PDF) |
| 525 | Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom MacroglobulinemiaBlood, 2008, 112, 832-832 | 4.2 | 7 | Citations (PDF) |
| 526 | Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study | 4.2 | 34 | Citations (PDF) |
| 527 | Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study | 4.2 | 17 | Citations (PDF) |
| 528 | Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma DrugsBlood, 2008, 112, 2648-2648 | 4.2 | 11 | Citations (PDF) |
| 529 | Immunomodulatory Effects of Lenalidomide and Bortezomib on Bone Marrow Stroma Cell and CD4 T Cell Interaction in Multiple Myeloma.Blood, 2008, 112, 1690-1690 | 4.2 | 0 | Citations (PDF) |
| 530 | The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.Blood, 2008, 112, 1716-1716 | 4.2 | 3 | Citations (PDF) |
| 531 | Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma TherapeuticsBlood, 2008, 112, 219-219 | 4.2 | 31 | Citations (PDF) |
| 532 | TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic ApplicationBlood, 2008, 112, 2737-2737 | 4.2 | 0 | Citations (PDF) |
| 533 | Emerging drugs in multiple myeloma | 2.4 | 11 | Citations (PDF) |
| 534 | Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Review and Update on the Use of Defibrotide | 2.6 | 41 | Citations (PDF) |
| 535 | New Drugs for Myeloma | 3.5 | 146 | Citations (PDF) |
| 536 | Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma | 6.9 | 71 | Citations (PDF) |
| 537 | The Treatment of Relapsed and Refractory Multiple Myeloma | 2.9 | 53 | Citations (PDF) |
| 538 | Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisBlood, 2007, 110, 1656-1663 | 4.2 | 109 | Citations (PDF) |
| 539 | Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibBlood, 2007, 109, 3177-3188 | 4.2 | 404 | Citations (PDF) |
| 540 | Novel therapies in myeloma | 2.8 | 18 | Citations (PDF) |
| 541 | High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials | 1.6 | 226 | Citations (PDF) |
| 542 | Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma | 2.6 | 12 | Citations (PDF) |
| 543 | Management of Relapsed and Relapsed Refractory Myeloma | 2.3 | 8 | Citations (PDF) |
| 544 | The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies | 2.3 | 111 | Citations (PDF) |
| 545 | From the bench to the bedside: emerging new treatments in multiple myeloma | 1.8 | 65 | Citations (PDF) |
| 546 | Toward a new therapeutic backbone in myelomaBlood, 2007, 109, 2672-2673 | 4.2 | 6 | Citations (PDF) |
| 547 | Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients | 6.1 | 36 | Citations (PDF) |
| 548 | Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment | 3.1 | 83 | Citations (PDF) |
| 549 | Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets | 61.8 | 866 | Citations (PDF) |
| 550 | Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma | 2.4 | 119 | Citations (PDF) |
| 551 | Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells | 2.4 | 102 | Citations (PDF) |
| 552 | From the bench to the bedside: emerging new treatments in multiple myeloma | 3.3 | 0 | Citations (PDF) |
| 553 | Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.Blood, 2007, 110, 1164-1164 | 4.2 | 18 | Citations (PDF) |
| 554 | Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.Blood, 2007, 110, 1165-1165 | 4.2 | 18 | Citations (PDF) |
| 555 | Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.Blood, 2007, 110, 1170-1170 | 4.2 | 10 | Citations (PDF) |
| 556 | Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.Blood, 2007, 110, 1179-1179 | 4.2 | 10 | Citations (PDF) |
| 557 | Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.Blood, 2007, 110, 1185-1185 | 4.2 | 2 | Citations (PDF) |
| 558 | Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.Blood, 2007, 110, 284-284 | 4.2 | 2 | Citations (PDF) |
| 559 | Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.Blood, 2007, 110, 4493-4493 | 4.2 | 1 | Citations (PDF) |
| 560 | Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.Blood, 2007, 110, 4496-4496 | 4.2 | 2 | Citations (PDF) |
| 561 | Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells.Blood, 2007, 110, 1519-1519 | 4.2 | 10 | Citations (PDF) |
| 562 | Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.Blood, 2007, 110, 2524-2524 | 4.2 | 1 | Citations (PDF) |
| 563 | Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.Blood, 2007, 110, 3507-3507 | 4.2 | 12 | Citations (PDF) |
| 564 | Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.Blood, 2007, 110, 4494-4494 | 4.2 | 1 | Citations (PDF) |
| 565 | In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway.Blood, 2007, 110, 540-540 | 4.2 | 1 | Citations (PDF) |
| 566 | Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.Blood, 2007, 110, 1509-1509 | 4.2 | 1 | Citations (PDF) |
| 567 | Antimyeloma activity of heat shock protein-90 inhibitionBlood, 2006, 107, 1092-1100 | 4.2 | 284 | Citations (PDF) |
| 568 | Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma | 2.4 | 89 | Citations (PDF) |
| 569 | The emerging role of novel therapeutic agents in the management of patients with multiple myeloma | 0.1 | 0 | Citations (PDF) |
| 570 | Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma | 1.9 | 49 | Citations (PDF) |
| 571 | Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy | 19.5 | 337 | Citations (PDF) |
| 572 | Defibrotide, a Polydisperse Mixture of Single-stranded Phosphodiester Oligonucleotides with Lifesaving Activity in Severe Hepatic Veno-occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action | 3.1 | 50 | Citations (PDF) |
| 573 | The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions | 5.1 | 193 | Citations (PDF) |
| 574 | Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cellsBlood, 2006, 107, 4053-4062 | 4.2 | 404 | Citations (PDF) |
| 575 | A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006, 108, 3458-3464 | 4.2 | 507 | Citations (PDF) |
| 576 | Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma | 2.2 | 33 | Citations (PDF) |
| 577 | Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies | 1.9 | 41 | Citations (PDF) |
| 578 | FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma | 2.4 | 4 | Citations (PDF) |
| 579 | Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: | 4.1 | 137 | Citations (PDF) |
| 580 | Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib | 21.6 | 612 | Citations (PDF) |
| 581 | Recent Advances in the Treatment of Multiple Myeloma | 2.3 | 15 | Citations (PDF) |
| 582 | Lenalidomide in multiple myeloma | 2.6 | 55 | Citations (PDF) |
| 583 | Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosisBlood, 2005, 106, 1794-1800 | 4.2 | 175 | Citations (PDF) |
| 584 | Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoBlood, 2005, 105, 4470-4476 | 4.2 | 59 | Citations (PDF) |
| 585 | Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application | 2.4 | 318 | Citations (PDF) |
| 586 | Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma | 2.4 | 183 | Citations (PDF) |
| 587 | Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors | 6.7 | 45 | Citations (PDF) |
| 588 | A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib | 38.5 | 699 | Citations (PDF) |
| 589 | Bortezomib in recurrent and/or refractory multiple myeloma | 4.1 | 221 | Citations (PDF) |
| 590 | Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma | 4.1 | 99 | Citations (PDF) |
| 591 | Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma | 21.6 | 70 | Citations (PDF) |
| 592 | Proteasome inhibitor therapy in multiple myeloma | 1.8 | 153 | Citations (PDF) |
| 593 | Bortezomib: proteasome inhibition as an effective anticancer therapy | 2.4 | 34 | Citations (PDF) |
| 594 | Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma | 7.6 | 586 | Citations (PDF) |
| 595 | Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaBlood, 2005, 106, 3777-3784 | 4.2 | 318 | Citations (PDF) |
| 596 | Proteasome inhibition as a therapeutic strategy for hematologic malignancies | 2.6 | 14 | Citations (PDF) |
| 597 | Plasma Cell Problems | 21.6 | 12 | Citations (PDF) |
| 598 | Proteasome Inhibition in the Treatment of Cancer | 3.3 | 94 | Citations (PDF) |
| 599 | Management of the Relapsed/Refractory Myeloma Patient: Strategies Incorporating Lenalidomide | 3.2 | 64 | Citations (PDF) |
| 600 | Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | 43.7 | 2,432 | Citations (PDF) |
| 601 | Emerging Trends in the Clinical Use of Bortezomib in Multiple Myeloma | 1.9 | 7 | Citations (PDF) |
| 602 | Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer | 21.6 | 537 | Citations (PDF) |
| 603 | Novel biological therapies for the treatment of multiple myeloma | 1.8 | 46 | Citations (PDF) |
| 604 | Proteasome inhibitors as therapeutics | 5.2 | 9 | Citations (PDF) |
| 605 | Multiple Myeloma | 2.9 | 78 | Citations (PDF) |
| 606 | Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma | 2.4 | 74 | Citations (PDF) |
| 607 | p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells | 6.7 | 134 | Citations (PDF) |
| 608 | An update of novel therapeutic approaches for multiple myeloma | 4.2 | 11 | Citations (PDF) |
| 609 | Proteasome inhibition in hematologic malignancies | 4.1 | 60 | Citations (PDF) |
| 610 | Case 38-2004 | 43.7 | 10 | Citations (PDF) |
| 611 | Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity | 3.1 | 122 | Citations (PDF) |
| 612 | A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation | 1.6 | 45 | Citations (PDF) |
| 613 | A review of the proteasome inhibitor bortezomib in multiple myeloma | 2.2 | 43 | Citations (PDF) |
| 614 | Immunomodulatory drug costimulates T cells via the B7-CD28 pathwayBlood, 2004, 103, 1787-1790 | 4.2 | 281 | Citations (PDF) |
| 615 | The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti–multiple myeloma (MM) activity and overcome bortezomib resistanceBlood, 2004, 103, 3158-3166 | 4.2 | 125 | Citations (PDF) |
| 616 | GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironmentBlood, 2004, 103, 3474-3479 | 4.2 | 90 | Citations (PDF) |
| 617 | Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cellsBlood, 2004, 104, 2458-2466 | 4.2 | 82 | Citations (PDF) |
| 618 | Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaBlood, 2004, 104, 4188-4193 | 4.2 | 181 | Citations (PDF) |
| 619 | Novel biologically based therapies for Waldenstrom's macroglobulinemia | 1.9 | 45 | Citations (PDF) |
| 620 | Recombinant humanized anti‐CD40 monoclonal antibody triggers autologous antibody‐dependent cell‐mediated cytotoxicity against multiple myeloma cells | 2.4 | 47 | Citations (PDF) |
| 621 | Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma | 6.7 | 166 | Citations (PDF) |
| 622 | A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma | 43.7 | 2,527 | Citations (PDF) |
| 623 | Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment | 2.8 | 134 | Citations (PDF) |
| 624 | The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003, 101, 2377-2380 | 4.2 | 686 | Citations (PDF) |
| 625 | Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieuBlood, 2003, 101, 703-705 | 4.2 | 115 | Citations (PDF) |
| 626 | Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood, 2003, 101, 1530-1534 | 4.2 | 547 | Citations (PDF) |
| 627 | Molecular sequelae of histone deacetylase inhibition in human malignant B cellsBlood, 2003, 101, 4055-4062 | 4.2 | 296 | Citations (PDF) |
| 628 | NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaBlood, 2003, 102, 2615-2622 | 4.2 | 222 | Citations (PDF) |
| 629 | Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationBlood, 2003, 102, 1578-1582 | 4.2 | 316 | Citations (PDF) |
| 630 | Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers | 2.4 | 287 | Citations (PDF) |
| 631 | Molecular sequelae of proteasome inhibition in human multiple myeloma cells | 7.6 | 704 | Citations (PDF) |
| 632 | Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applicationsBlood, 2002, 99, 4079-4086 | 4.2 | 373 | Citations (PDF) |
| 633 | 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cellsBlood, 2002, 100, 2187-2194 | 4.2 | 111 | Citations (PDF) |
| 634 | Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002, 100, 3063-3067 | 4.2 | 772 | Citations (PDF) |
| 635 | Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcomeBlood, 2002, 100, 4337-4343 | 4.2 | 335 | Citations (PDF) |
| 636 | Thalidomide: Emerging Role in Cancer Medicine | 19.5 | 130 | Citations (PDF) |
| 637 | NF-κB as a Therapeutic Target in Multiple Myeloma | 2.2 | 845 | Citations (PDF) |
| 638 | Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood, 2002, 99, 4525-4530 | 4.2 | 651 | Citations (PDF) |
| 639 | Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays | 6.7 | 173 | Citations (PDF) |
| 640 | Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications | 6.7 | 466 | Citations (PDF) |
| 641 | Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 4.2 | 897 | Citations (PDF) |
| 642 | Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration | 4.2 | 406 | Citations (PDF) |
| 643 | TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications | 4.2 | 364 | Citations (PDF) |
| 644 | The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications | 6.7 | 388 | Citations (PDF) |
| 645 | Novel therapies targeting the myeloma cell and its bone marrow microenvironment | 1.9 | 171 | Citations (PDF) |
| 646 | Novel therapies targeting the myeloma cell and its bone marrow microenvironment | 1.9 | 130 | Citations (PDF) |
| 647 | Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence | 2.2 | 7 | Citations (PDF) |
| 648 | Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood, 2000, 96, 2943-2950 | 4.2 | 857 | Citations (PDF) |
| 649 | Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome | 21.6 | 51 | Citations (PDF) |
| 650 | THE PATHOLOGY, DIAGNOSIS, AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE: CURRENT STATUS AND NOVEL APPROACHES | 2.4 | 86 | Citations (PDF) |
| 651 | Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors 1998, 83, 409-414 | | 37 | Citations (PDF) |
| 652 | Prevention and Treatment of Hepatic Venocclusive Disease after High-Dose Cytoreductive Therapy | 1.5 | 23 | Citations (PDF) |
| 653 | Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon? | 1.3 | 8 | Citations (PDF) |
